Oppenheimer Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock

Ligand Pharmaceuticals (NASDAQ:LGND) had its target price raised by stock analysts at Oppenheimer from $275.00 to $277.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price target points to a potential upside of 39.68% from the stock’s previous close.

A number of other analysts have also recently commented on the company. Stifel Nicolaus upped their price objective on Ligand Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Weiss Ratings restated a “hold (c)” rating on shares of Ligand Pharmaceuticals in a research note on Monday, December 29th. Royal Bank Of Canada upped their price target on shares of Ligand Pharmaceuticals from $234.00 to $235.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Benchmark increased their price objective on shares of Ligand Pharmaceuticals from $175.00 to $220.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Finally, Citigroup assumed coverage on shares of Ligand Pharmaceuticals in a report on Tuesday, December 9th. They issued a “buy” rating and a $270.00 price objective on the stock. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Ligand Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $245.17.

Ligand Pharmaceuticals Stock Performance

Shares of LGND stock opened at $198.31 on Friday. The company has a quick ratio of 24.30, a current ratio of 24.69 and a debt-to-equity ratio of 0.47. The company has a 50 day moving average price of $193.46 and a 200-day moving average price of $185.59. Ligand Pharmaceuticals has a 52 week low of $93.58 and a 52 week high of $212.49. The firm has a market capitalization of $3.90 billion, a PE ratio of 34.02 and a beta of 1.14.

Ligand Pharmaceuticals (NASDAQ:LGND) last posted its earnings results on Thursday, February 26th. The biotechnology company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.56. The business had revenue of $59.67 million during the quarter, compared to the consensus estimate of $55.59 million. Ligand Pharmaceuticals had a net margin of 46.42% and a return on equity of 14.50%. The firm’s revenue was up 39.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.27 EPS. Ligand Pharmaceuticals has set its FY 2026 guidance at 8.000-9.000 EPS. As a group, equities research analysts expect that Ligand Pharmaceuticals will post 1.73 earnings per share for the current year.

Insider Activity

In related news, CFO Octavio Espinoza sold 1,804 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $188.31, for a total transaction of $339,711.24. Following the completion of the transaction, the chief financial officer directly owned 26,186 shares in the company, valued at approximately $4,931,085.66. The trade was a 6.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John W. Kozarich sold 467 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $195.91, for a total transaction of $91,489.97. Following the sale, the director owned 43,187 shares in the company, valued at approximately $8,460,765.17. The trade was a 1.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,205 shares of company stock worth $611,192 in the last ninety days. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of Ligand Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Ashton Thomas Private Wealth LLC lifted its stake in shares of Ligand Pharmaceuticals by 2.9% during the 3rd quarter. Ashton Thomas Private Wealth LLC now owns 2,014 shares of the biotechnology company’s stock valued at $357,000 after buying an additional 56 shares in the last quarter. Maryland State Retirement & Pension System increased its stake in Ligand Pharmaceuticals by 2.2% in the 4th quarter. Maryland State Retirement & Pension System now owns 2,872 shares of the biotechnology company’s stock worth $543,000 after buying an additional 61 shares in the last quarter. GAMMA Investing LLC raised its holdings in Ligand Pharmaceuticals by 12.3% during the third quarter. GAMMA Investing LLC now owns 575 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 63 shares during the period. Smartleaf Asset Management LLC raised its holdings in Ligand Pharmaceuticals by 31.6% during the third quarter. Smartleaf Asset Management LLC now owns 271 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 65 shares during the period. Finally, CIBC Private Wealth Group LLC lifted its position in shares of Ligand Pharmaceuticals by 86.3% in the third quarter. CIBC Private Wealth Group LLC now owns 149 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 69 shares in the last quarter. 91.28% of the stock is owned by hedge funds and other institutional investors.

Ligand Pharmaceuticals News Summary

Here are the key news stories impacting Ligand Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations — non-GAAP EPS $2.02 vs. $1.46 est. and revenue $59.7M vs. $55.6M est.; revenue rose ~39.5% year-over-year, underpinning near-term momentum. Earnings Beat Article
• Positive Sentiment: Management issued very strong FY2026 guidance: adjusted EPS $8.00–$9.00 (vs. consensus ~$4.85) and revenue $245M–$285M (around consensus), signaling meaningful upside to street profitability expectations. Press Release
• Positive Sentiment: Analyst support: Oppenheimer raised its price target to $277 and kept an “outperform” rating, pointing to significant upside from current levels. Analyst Note
• Positive Sentiment: Longer-term growth thesis reinforced — company projects a ~23% CAGR in royalty revenues through 2030 and reported ~48% full-year royalty revenue growth for 2025, supporting durable cash-flow expectations. Royalty Growth Outlook
• Neutral Sentiment: Earnings-call materials and transcripts are available for detail review — useful to confirm drivers (one-time items, royalty composition, cadence of royalty receipts). Review the call transcript and highlights for management color. Earnings Call Transcript Earnings Highlights
• Neutral Sentiment: Other analysts voiced bullish views (e.g., HC Wainwright), which can support sentiment but are not new fundamental data. Analyst Commentary
• Negative Sentiment: Some short-term selling pressure was reported (an article noted ~6% intraday weakness) — likely profit-taking and valuation concerns (LGND’s high P/E) after sharp moves; monitor whether investors question sustainability of the elevated EPS guidance or attribute upside to non-recurring items. Why Stock Fell

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.